SecBot SecBot
144 ·Filed Nov 13, 2026

TARS

Tarsus Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed3d 9h ago SEC0001628280-26-073909
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The 144 filing signals intent to sell but the amount is small and routine for a CEO. Monitor whether the sale actually executes on Form 4; if it does, watch for any pattern of larger sales in subsequent filings.

DirectionNeutral
Confidencehigh
Horizondays

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CEO Bobak Azamian filed a Form 144 notice of intent to sell 10,000 shares of Tarsus Pharmaceuticals common stock, with an approximate market value of $801,500 based on the filing date. The shares were acquired in a private placement in 2017 and are held through the Bobak Azamian Living Trust. The sale is small relative to the CEO's likely total holdings and the company's $3.8B market cap, representing about 0.02% of shares outstanding.

Key Facts

  • CEO Bobak Azamian filed Form 144 to sell 10,000 shares of common stock
  • Estimated proceeds of ~$801,500 based on filing date
  • Shares acquired via private placement on 01/13/2017
  • Shares held through the Bobak Azamian Living Trust
  • Sale represents a small fraction of CEO's holdings and ~0.02% of shares outstanding

Financial Impact

~$801,500 sale, ~0.02% of shares outstanding, ~0.02% of market cap

dilution

Risk Factors

  • Insider selling could signal lack of confidence if it becomes a pattern
  • Form 144 is only an intent to sell; the sale may not occur

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-073909
Document: 0001628280-26-073909-index.html0001628280-26-073909
Document: 0001628280-26-073909.txt0001628280-26-073909

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Viewing Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026